← Back to Search

Procedure

Brain Stimulation for Depression

N/A
Waitlist Available
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Medication-refractory epilepsy requiring phase II monitoring
Men and women, ages 18 to 65
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 45 minutes

Summary

This trial aims to identify markers of brain activity to better understand how TMS treatments work to help treat depression & other psychiatric disorders.

Who is the study for?
This trial is for men and women aged 18 to 65 who have medication-resistant epilepsy needing detailed monitoring, and are able to understand the study's risks to give informed consent. It excludes those with major neurological disorders besides epilepsy.
What is being tested?
The study tests how repetitive brain stimulation affects the brain using TMS (a noninvasive treatment for depression) and intracranial electrodes. It aims to identify precise brain activity markers that can enhance TMS effectiveness for treating depression.
What are the potential side effects?
TMS may cause discomfort at the stimulation site, headaches, lightheadedness, or seizures in rare cases. Intracranial electrode placement involves surgical risks like infection, bleeding, or damage to surrounding tissues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My epilepsy does not improve with medication and needs special monitoring.
Select...
I am between 18 and 65 years old.
Select...
I have epilepsy but no other major neurological disorders.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~45 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 45 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
TMS-iEEG change after one TBS session
Secondary study objectives
ES-iEEG change after one TBS session
ES-iEEG change between two sequential TBS sessions
TMS-iEEG change between two sequential TBS sessions

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: TBS via direct electrical stimulationActive Control1 Intervention
Group II: TBS via transcranial magnetic stimulationActive Control1 Intervention
Group III: Sham TBS via direct electrical stimulationPlacebo Group1 Intervention
Group IV: Sham TBS via transcranial magnetic stimulationPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,467 Previous Clinical Trials
17,496,053 Total Patients Enrolled
16 Trials studying Epilepsy
1,174 Patients Enrolled for Epilepsy
Massachusetts General HospitalOTHER
3,006 Previous Clinical Trials
13,307,233 Total Patients Enrolled
8 Trials studying Epilepsy
589 Patients Enrolled for Epilepsy
University of IowaOTHER
465 Previous Clinical Trials
893,222 Total Patients Enrolled
3 Trials studying Epilepsy
710 Patients Enrolled for Epilepsy
~31 spots leftby Jan 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top